Rosiglitazone, a peroxisome proliferator-activated receptor-γ ligand, reduces infarction volume and neurological deficits in an embolic model of stroke

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 11, 2006, Pages 1052-1058

  Allahtavakoli, Mohammad ^a   Shabanzadeh, Alireza P ^a,b   Sadr, Seyed Shahabeddin ^a   Parviz, Mohsen ^a   Djahanguiri, Bijan ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Embolism; Rat; Rosiglitazone; Stroke; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIMETHYL SULFOXIDE; GLUTAMIC ACID; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN EDEMA; BRAIN EMBOLISM; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EXCITOTOXICITY; IMAGE PROCESSING; INFLAMMATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVOUS SYSTEM FUNCTION; NEUROLOGIC DISEASE; NONHUMAN; RAT; STAINING; STROKE; TISSUE SECTION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN EDEMA; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; PPAR GAMMA; RATS; STROKE; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 33750054375     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04486.x     Document Type: Article

References (35)

1. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations. Lancet 1999; 354: 1457-63.
2. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: New opportunities for novel therapeutics. J. Cereb. Blood Flow Metab. 1999; 19: 819-34.
3. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. 2004; 61: 657-68.
4. Ringel R, Schmid-Elaster R. Antioxidants for CNS ischemia and trauma. Expert Opin. Ther. Patents 2001; 11: 987-97.
5. Smith WS. Pathophysiology of focal cerebral ischemia: A therapeutic perspective. J. Vasc. Interv. Radiol. 2004; 15 (Suppl.): S3-12.
6. Lee JM, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 1999; 399 (Suppl.): A7-14.
7. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 1995; 44: 486-90.
8. Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 1991; 40: 1268-74.
9. Stumvoll M, Haring HU. Glitazones: Clinical effects and molecular mechanisms. Ann. Med. 2002; 34: 217-24.
10. Parker JC. Troglitazone: The discovery and development of a novel therapy for the treatment of type 2 diabetes mellitus. Adv. Drug Deliv. Rev. 2002; 54: 1173-97.
11. Sundararajan S, Landreth GE. Antiinflammatory properties of PPAR-gamma agonists following ischemia. Drug News Perspect. 2004; 17: 229-36.
12. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005; 130: 685-96.
13. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPAR-gamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl Acad. Sci. USA 2003; 100: 6295-6.
14. Uryu S, Harada J, Hisamoto M, Oda T. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 2002; 924: 229-36.
15. Fonseca VA, Reynolds T, Hemphill D et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with noninsulin-dependent diabetes mellitus. J. Diabetes Complications 1998; 12: 181-6.
16. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-9.
17. Aoun P, Simpkins JW, Agarwal N. Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2003; 44: 2999-3004.
18. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2002; 2: 748-59.
19. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 2000; 20: 6862-7.
20. Dello Russo C, Gavrilyuk V, Weinberg G et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 2003; 278: 5828-36.
21. Pereira MP, Hurtado O, Cardenas A et al. Rosiglitazone and 15-deoxydelta(12,14)-prostaglandin J(2) cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb. Blood Flow Metab. 2006; 26: 218-29.
22. Wang CX, Yang T, Shuaib A. An improved version of embolic model of brain ischemic injury in the rat. J. Neurosci. Methods 2001; 109: 147-51.
23. Sloan MA. Thrombolysis and stroke. Past and future. Arch. Neurol. 1987; 44: 748-68.
24. Chakrabarti R, Vikramadithyan RK, Kumar MP et al. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. Diabetes Obes. Metab. 2002; 4: 319-28.
25. Asahi M, Huang Z, Thomas S et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2005; 25: 722-9.
26. Shuaib A, Wang CX, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke 2002; 33: 3033-7.
27. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472-6.
28. Franowicz JS, Arnsten AF. Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype. Psychopharmacology 2002; 162: 304-12.
29. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972; 32: 281-94.
30. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004; 123: 131-45.
31. Megherbi S-E, Milan C, Minier D et al. Association between diabetics and stroke subtype on survival and functional outcome 3 months after stroke: Data from the European BIOMED stroke project. Stroke 2003; 34: 688-94.
32. Wargent E, Stocker C, Augstein P et al. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: Comparison with and combination with rosiglitazone. Diabetes Obes. Metab. 2005; 7: 170-81.
33. Shimizu S, Simon RP, Graham SH. Dimethylsulfoxide (DMSO) treatment reduces infarction volume after permanent focal cerebral ischemia in rats. Neurosci. Lett. 1997; 19: 125-7.
34. Zausinger S, Baethmann A, Schmid-Elsaesser R. Anesthetic methods in rats determine outcome after experimental focal cerebral ischemia: Mechanical ventilation is required to obtain controlled experimental conditions. Brain Res. Protocols 2002; 9: 112-21.
35. 31P MRS of tumour metabolism in anaesthetized vs conscious mice. NMR Biomed. 1994; 7: 167-71.